Disc Medicine Inc IRON

$78.93 +22.09 (38.86%)

Valuation

Market cap
217,958,000
Revenue TTM
$0
Net income TTM
$-212,180,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.09

Trading

Volume
8,477,063
Avg volume
535,882
Day's range
$69.98 – $80.22
Shares out
3,835,000
Stochastic %K
19%
Beta
0.93
Analysts
Strong Sell
Price target
$103.17

Price

Company profile

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formati...

Show more

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 674 9274
Website
https://www.discmedicine.com
Address
321 Arsenal Street, Suite 101, Watertown, United States

Latest news

Stocktwits

RTPRwire Oct 19, 9:31 PM
Today's biggest catalyst moves on the wire (validated intraday captures through 5:15 PM ET): $WORX ran as much as +156% — partnership $EXYN ran as much as +59% — contract win $MASK.X ran as much as +46% — contract win $IRON ran as much as +45% — clinical trial results $YMAT ran as much as +35% — partnership Get real-time catalyst alerts using RTPR.
0 replies
BiotechSwings Oct 19, 9:25 PM
Monday close, and biotech finally exhaled $XBI closed 147.86, up 2.45 percent, back over the 200 day at 146.87 after that ugly Friday close at 144.32 $IBB closed 204.06, up 1.02 percent, still under the 50 day at 206.36 but holding well above its 200 day $SLN up 125 percent to 19.58 on the Merck KGaA deal at 20 cash $IRON up 38.9 percent to 78.93, APOLLO hit everything, PPIX down 41.4 percent MANE up 12.4 percent and AGIO up 11.4 percent right behind them $EYPT is the other side of binary day. wet AMD program ends, and the DME Phase 3 clock into late 2027 is the story left standing imo nothing binary landing Tuesday. the week builds to Oct 24, Pharming PDUFA and Moderna ESMO data
0 replies
M105 Oct 19, 9:21 PM
$IRON Keep talking NONSENSE.. your misery just got started. See you at $120+ tomorrow 🤣
0 replies
MrLemonMan Oct 19, 9:13 PM
$IRON this is a short up here yahooo
0 replies
Benjamin2020 Oct 19, 9:11 PM
$IRON why not announce the offering price? It’s probably terrible and in the low 60’s
0 replies
VolumeSpreadAnalysis Oct 19, 9:06 PM
$IRON Price: $78.93 Volume: Above average Catalyst: Reports of a potential supply agreement in the iron ore/steel space are fueling speculation and heavier-than-usual trading interest. Resistance: $82.50 Support: $75.00 Bull case: A clean break above $82.50 on sustained volume could open the door to a fresh leg higher toward $86-88. Bear case: Failure to hold $75 support on rising volume may signal exhaustion and trigger a slide back toward $70. What I'm watching: Watching for a volume-confirmed close above resistance or a breakdown below support to gauge the next directional move. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services. Feel free to check out the link in my bio: @VolumeSpreadAnalysis
0 replies
BiotechSwings Oct 19, 8:56 PM
Trending for a reason imo. $IRON APOLLO just linked what the FDA said was missing back in February. PPIX down 41.4 percent vs placebo, 12.2 more hours in light without pain in month 6, 183 patients, no new safety flags. Resubmit by year end, decision mid 2027
0 replies
M105 Oct 19, 8:53 PM
$IRON Lol… Utter nonsense See you at $$128+
1 replies